Evidence supporting the use of: Alpha-GPC
For the health condition: Senility
Synopsis
Source of validity: Scientific
Rating (out of 5): 3
Alpha-GPC (L-alpha-glycerylphosphorylcholine) is a choline-containing phospholipid that has been studied for its potential to support cognitive function, particularly in the context of age-related cognitive decline and senility (often referring to symptoms of dementia or Alzheimer's disease). There is moderate scientific evidence supporting its use in this context. Several randomized controlled trials, mostly conducted in Italy in the 1990s and early 2000s, have investigated Alpha-GPC in elderly patients with cognitive impairment. Some studies have found that Alpha-GPC supplementation (typically 400-1200 mg/day) improved memory, attention, and other cognitive functions compared to placebo or other choline sources. Proposed mechanisms include increasing acetylcholine synthesis in the brain and supporting neuronal membrane health.
A 2003 meta-analysis by Parnetti et al. reviewed these clinical trials and concluded that Alpha-GPC had statistically significant benefits on cognition in patients with dementia of the Alzheimer type, vascular dementia, and mixed forms. However, the methodological quality of these studies varies, and most were relatively short-term (up to 6 months). There is a lack of large, modern, multinational trials, and the studies were mostly in populations with mild to moderate cognitive impairment. Therefore, while there is scientific validation for Alpha-GPC's use in supporting cognitive function in senility, the strength of evidence is moderate (rated 3/5) and further research is warranted to confirm its efficacy and safety.
Other health conditions supported by Alpha-GPC
Aging (prevention)Alzheimer's Disease
Athletic and Exercise Aids
Concentration (poor)
Confusion
Dementia
Memory and Brain Function
Senility
Thinking (cloudy)